Access and Patient Support

Making your patients’ support needs a priority. Together.

At Pfizer Oncology Together™, patient support is at the core of everything we do. We’ve gathered resources and developed tools to help patients and their loved ones throughout DAURISMO treatment.

Card CTA

Patient financial assistance

Medicare/government insured

Help identifying resources for eligible patients with Medicare/Medicare Part D, Medicaid, and other government insurance plans:
​​​​​​​
  • Assistance for patients with searching for financial support that may be available from independent charitable foundations. These foundations exist independently of Pfizer and have their own eligibility criteria and application processes. Availability of support from the foundations is determined solely by the foundations
  • Financial assistance through Extra Help, a Medicare Part D Low-Income Subsidy (LIS) program
  • Free medication*

Uninsured

Help identifying resources for eligible patients without any form of healthcare coverage:

  • Help finding coverage
  • Free medication through the Pfizer Patient Assistance Program, or at a savings through the Pfizer Savings Program​​​​​​​​​​​​​​​​​​​​​

   *If support from independent charitable foundations or Medicare Extra Help is not available, Pfizer Oncology Together will provide eligible patients with medication for free through the Pfizer Patient Assistance Program. The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.

   The Pfizer Savings Program is not health insurance. For more information, call the toll-free number 1-877-744-5675. There are no membership fees to participate in this program. Estimated savings are 50% and depend on such factors as the particular drug purchased, amount purchased, and the pharmacy where purchased.

FOR LIVE, PERSONALIZED SUPPORT

Call 1-877-744-5675
​​​​​​​(Monday—Friday ​​​​​​​8 AM—8 PM ET)

PfizerOncology​Together.com 

Personalized patient support

When your patients need support for their day-to-day challenges, we want to be a place they can turn to for help. At Pfizer Oncology Together, our Care Champions, who have social work experience, can connect patients prescribed DAURISMO to resources that may help with some of their daily needs.

  • Emotional Support We can connect patients to diagnosis-specific support groups, an independent organization that offers short-term counseling, and a free app, developed by Pfizer Oncology, to help patients connect with loved ones and ask for the support they need
  • Educational Support To help support patients’ overall health and well-being, we’ve created resources about physical and mental health, as well as nutritional tips and healthy recipes developed in partnership with dietitians who specialize in oncology nutrition. We can also provide patients with information to help them understand their prescribed DAURISMO
  • Practical Support If patients need assistance with transportation or lodging for treatment-related appointments, we’ll connect them to independent organizations that offer these services for free to qualifying patients.
And if your patients are leaving work for a period of time during treatment, or preparing to return to work, we can send them information to help make the transition easier
​​​​​​​

    ‡Some services are provided through third-party organizations that operate independently and are not controlled by Pfizer. Availability of services and eligibility requirements are determined solely by these organizations.

FOR LIVE, PERSONALIZED SUPPORT

Call 1-877-744-5675
​​​​​​​(Monday—Friday ​​​​​​​8 AM—8 PM ET)

PfizerOncology​Together.com 

Access & reimbursement support

If patients prescribed DAURISMO need access or reimbursement support, Pfizer Oncology Together is here to help with:

Benefits verification:

We can help determine a patient’s coverage and out-of-pocket costs

Prior authorization (PA) assistance:

We can coordinate with a patient’s insurer to determine the PA requirements. After your office submits a PA request, we'll follow up with the payer until a final outcome is determined

Appeals assistance:

We can review the reasons for a denied claim and provide information on payer requirements. After your office submits an appeal request, we'll follow up with the payer until a final outcome is determined

Specialty pharmacy coordination:

To help your patients access the medication you’ve prescribed, we can identify specialty pharmacy options. If you prefer, you and your staff can also continue to work directly with specialty pharmacies

Dedicated local support:

Pfizer Oncology Account Specialists can provide detailed information on Pfizer Oncology medications and access resources. In addition, they can help you and your office staff contact a Pfizer Field Reimbursement Manager (FRM) in your area.
​​​​​​​
FRMs are trained to help address specific access issues—in person or over the phone. They can help educate your staff on our access and reimbursement resources and help address challenging or urgent Pfizer Oncology patient cases you have sent to Pfizer Oncology Together.

FOR LIVE, PERSONALIZED SUPPORT

Call 1-877-744-5675
​​​​​​​(Monday—Friday ​​​​​​​8 AM—8 PM ET)

PfizerOncology​Together.com 

Support Your Patient

  • Access and Patient Support
  • Specialty Pharmacies
  • Downloadable Resources and Publications
View Support & Services

Safety Profile

The safety profile of DAURISMO + LDAC was established in older patients not eligible for intensive chemotherapy

Find out more

** This is an optional area where footnotes can live.

Downloadable Resources

Access helpful resources to support DAURISMO treatment

See available resources

** This is an optional area where footnotes can live.

WARNING: EMBRYO-FETAL TOXICITY: DAURISMO can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. DAURISMO is embryotoxic, fetotoxic, and teratogenic in animals. Conduct pregnancy testing in females of reproductive potential prior to initiation of DAURISMO treatment. Advise females of reproductive potential to use effective contraception during treatment with DAURISMO and for at least 30 days after the last dose. Advise males of the potential risk of DAURISMO exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with DAURISMO and for at least 30 days after the last dose to avoid potential drug exposure.

Blood Donation: Advise patients not to donate blood or blood products while taking DAURISMO and for at least 30 days after the last dose, because their blood or blood products might be given to a female of reproductive potential.

QTc Interval Prolongation: Patients treated with DAURISMO can develop QTc prolongation and ventricular arrhythmias, including ventricular fibrillation and ventricular tachycardia. Of the 98 evaluable patients treated with DAURISMO 100 mg in combination with low-dose cytarabine in the clinical trial, 5% were found to have a QTc interval greater than 500 ms and 4% of patients had an increase from baseline QTc greater than 60 ms. The clinical trial excluded patients with baseline QTc of greater than 470 ms or with a history of long QT syndrome or uncontrolled cardiovascular disease. Monitor electrocardiograms (ECGs) and electrolytes. Concomitant use of DAURISMO with drugs known to prolong the QTc interval and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. In patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring is recommended. Interrupt DAURISMO if QTc interval is >500 ms and discontinue permanently for patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.

Adverse Reactions: Most common adverse reactions associated with DAURISMO (incidence ≥20%) were anemia (43%), fatigue (36%), hemorrhage (36%), febrile neutropenia (31%), musculoskeletal pain (30%), edema (30%), thrombocytopenia (30%), nausea (29%), dyspnea (23%), decreased appetite (21%), dysgeusia (21%), mucositis (21%), constipation (20%), and rash (20%).

Drug Interactions: Co-administration with strong CYP3A4 inhibitors increased DAURISMO plasma concentrations, which may increase the risk of adverse reactions including QTc interval prolongation. Consider alternative therapies that are not strong CYP3A4 inhibitors during treatment with DAURISMO and monitor patients for increased risk of adverse reactions including QTc interval prolongation. Strong and moderate CYP3A4 inducers should be avoided due to decreased DAURISMO plasma concentrations, which may reduce efficacy. If concomitant use of moderate CYP3A4 inducers cannot be avoided, increase the DAURISMO dosage to 200 mg once daily (if the patient is taking 100 mg) and 100 mg once daily (if the patient is taking 50 mg) as tolerated. Co-administration of DAURISMO with QTc-prolonging drugs may increase the risk of QTc interval prolongation. Avoid co-administration of QTc-prolonging drugs with DAURISMO or replace with alternative therapies. If co-administration of a QTc-prolonging drug is unavoidable, monitor patients for increased risk of QTc interval prolongation.

Lactation: Because of the potential for serious adverse reactions from DAURISMO in a breastfed child, advise women who are taking DAURISMO not to breastfeed or provide breast milk to infants or children during treatment and for at least 30 days after the last dose.

Renal Impairment: No dosage modification is recommended for patients with mild to severe renal impairment. Monitor patients with severe renal impairment (eGFR 15 to 29 mL/min) for increased risk of adverse reactions, including QTc interval prolongation, due to increased glasdegib concentrations.

DAURISMO is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

Indication

DAURISMOTM is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.